Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630697 | 0.95 | SMN1; SMN2 (0.73) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL3271568 | 0.91 | ALDH1A1 (0.70) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL3271535 | 0.91 | ALDH1A1 (0.70) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL1468838 | 0.91 | ALDH1A1 (0.70) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL31170470 | 0.89 | SMN1; SMN2 (0.69) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL31170142 | 0.89 | SMN1; SMN2 (0.69) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL31170255 | 0.89 | SMN1; SMN2 (0.69) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL25030784 | 0.88 | SMN1; SMN2 (0.64) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL5766528 | 0.88 | NPC1 (0.66) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL15610237 | 0.87 | SMN1; SMN2 (0.62) | NPC1SMN1; SMN2RAB9ACYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2020-04-09 | — | — | US | disclosed |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-08-23 | — | — | US | disclosed |
| EP-3261639-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | Verseon Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138532-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | NPC1 2956/4885SMN1; SMN2 4264/4885RAB9A 1843/4885 |
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | NPC1 1969/4885SMN1; SMN2 3676/4885RAB9A 2110/4885 |
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | NPC1 1969/4885SMN1; SMN2 3676/4885RAB9A 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.